WELL Health Reports $25.6 Million In Revenue For Q1, Net Loss
WELL Health Technologies (TSX: WELL) this morning reported its first quarter 2021 financial results, reporting $25.6 million in revenue for the period along with a net loss of $7.1 million, or a loss of $0.04 per share. On an adjusted EBITDA basis, the company generated just $0.5 million in positive EBITDA.
Revenue for the period was reportedly a record on a quarterly basis, with revenues increasing 150% on a year over year basis from Q1 2020’s revenue of $10.2 million, and an improvement from the $17.2 million recognized in the fourth quarter. With a cost of sales of $15.5 million for the quarter, “adjusted” gross margins came in at 39.3%, with unadjusted numbers not yet filed by the company.
Notably, while the company technically hit its guidance of adjusted EBITDA improving for its Canadian operations, which saw the figure rise to $1.1 million from $417,000 in the fourth quarter, the company posted declining adjusted EBITDA on an overall quarter over quarter basis. The fourth quarter saw $765,000 in adjusted EBITDA, while the current quarter saw just $527,000.
In terms of outlook, the company remains persistent that it will achieve an annualized revenue run rate of $300 million, much of which is to come from the recently acquired CRH Medical. The company has also stated it is committed to achieving organic growth, continue with acquisitions, grow EBITDA, increase operating cash flows, and increase the market share of its digital health products.
WELL Health last traded at $7.31 on the TSX.
Information for this briefing was found via Sedar and WELL Health Technologies Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
